Cargando…
551. MK-8591 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel
BACKGROUND: Over 2 million girls and young women are living with HIV, being newly infected at disproportionately high rates. HIV infection adds risks to pregnancy, including vertical transmission and maternal death. Hormonal contraceptives are among the most effective reversible contraceptives, but...
Autores principales: | Ankrom, Wendy, Jonathan, Daniel, Rudd, Deanne, Zhang, Sandra, Fillgrove, Kerry, Gravesande, Kezia, Matthews, Randolph, Brimhall, Darin, Stoch, Aubrey, Iwamoto, Marian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255447/ http://dx.doi.org/10.1093/ofid/ofy210.559 |
Ejemplares similares
-
A phase 1, open‐label study to evaluate the drug interaction between islatravir (MK‐8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females
por: Ankrom, Wendy, et al.
Publicado: (2021) -
546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration
por: Matthews, Randolph, et al.
Publicado: (2018) -
A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021) -
Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV
por: Matthews, Randolph P., et al.
Publicado: (2021) -
The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives
por: Bonnema, Rachel A., et al.
Publicado: (2011)